Gilead advances, lifts averages, after offering more detail on remdesivir Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Gilead (GILD) up 3% after announcing additional data on remdesivir, an investigational antiviral for the treatment of COVID-19
- Matson (MATX) up 21% after
issuing Q2 guidance above consensus
- Ziopharm (ZIOP) up 1% after initiating a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its rapid personalized manufacturing technology, as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas
- Autoliv (ALV) up 4% after Goldman Sachs analyst Gungun Verma initiated coverage of shares with a Buy rating and a price target of $81
UP AFTER EARNINGS -
- Greenbrier (GBX) up 13%
- Simulations Plus (SLP) up 10%
LOWER -
- Beyond Meat (BYND) down 3% after Citi analyst Wendy Nicholson initiated coverage of the stock with a Sell rating and $123 price target
- Santander Consumer (SC) down 1% after announcing it does not expect to pay dividend in Q3
- Fastly (FSLY) down 3% after BofA analyst Tal Liani double-downgraded shares to Underperform from Buy but raised his price target to $90, up from $50
- Transocean (RIG) down 2% after Bloomberg reported the company expects to cut 110 workers in Texas
- Centogene (CNTG) down 16% after its 3.5M share secondary offering priced at $14.00 per share
Symbols:
GILD ZIOP ALV MATX GBX SLP BYND - $141.13 /
-3.735 (-2.58%)
SC FSLY RIG CNTG Keywords: Fly Intel, Wall Street, Top Stories, Stocks